Associations - HR negative

HR negative HR negative	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	HR negative HR negative	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: A2 - Guideline	trastuzumab + pertuzumab Sensitive: A2 - Guideline
HR negative HR negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR negative HR negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
HR negative HR negative	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	HR negative HR negative	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab + lapatinib Sensitive: B - Late Trials	trastuzumab + lapatinib Sensitive: B - Late Trials
HR negative HR negative	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	HR negative HR negative	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab Sensitive: C2 – Inclusion Criteria	trastuzumab Sensitive: C2 – Inclusion Criteria
HR negative HR negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR negative HR negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	carboplatin + paclitaxel Sensitive: C2 – Inclusion Criteria	carboplatin + paclitaxel Sensitive: C2 – Inclusion Criteria
HR negative HR negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR negative HR negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	olaparib Sensitive: C3 – Early Trials	olaparib Sensitive: C3 – Early Trials
HR negative HR negative	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	HR negative HR negative	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	tegafur/uracil Sensitive: C3 – Early Trials	tegafur / uracil Sensitive: C3 – Early Trials
HR negative HR negative	Hormone Receptor Negative Breast Cancer Hormone Receptor Negative Breast Cancer	HR negative HR negative	Hormone Receptor Negative Breast Cancer Hormone Receptor Negative Breast Cancer	TCHP Sensitive: C3 – Early Trials	TCHP Sensitive: C3 – Early Trials
HR negative HR negative	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	HR negative HR negative	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	pertuzumab Sensitive: C3 – Early Trials	pertuzumab Sensitive: C3 – Early Trials
HR negative HR negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR negative HR negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	AMG 479 Sensitive: C3 – Early Trials	AMG 479 Sensitive: C3 – Early Trials
HR negative HR negative	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	HR negative HR negative	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	ado-trastuzumab emtansine + pertuzumab Sensitive: C3 – Early Trials	ado-trastuzumab emtansine + pertuzumab Sensitive: C3 – Early Trials
HR negative HR negative	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	HR negative HR negative	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	lapatinib Sensitive: C3 – Early Trials	lapatinib Sensitive: C3 – Early Trials
HR negative HR negative	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	HR negative HR negative	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	pembrolizumab + pertuzumab + Trazimera (trastuzumab biosimilar) Sensitive: C3 – Early Trials	pembrolizumab + pertuzumab + Trazimera (trastuzumab biosimilar) Sensitive: C3 – Early Trials
HR negative HR negative	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	HR negative HR negative	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab + pyrotinib Sensitive: C3 – Early Trials	trastuzumab + pyrotinib Sensitive: C3 – Early Trials
HR negative HR negative	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	HR negative HR negative	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	ado-trastuzumab emtansine Sensitive: C4 – Case Studies	ado-trastuzumab emtansine Sensitive: C4 – Case Studies
HR negative HR negative	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	HR negative HR negative	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	CDK19 inhibitor Sensitive: D – Preclinical	CDK19 inhibitor Sensitive: D – Preclinical
HR negative HR negative	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	HR negative HR negative	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	CDK8 inhibitor Sensitive: D – Preclinical	CDK8 inhibitor Sensitive: D – Preclinical
HR negative HR negative	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	HR negative HR negative	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	RVU120 Sensitive: D – Preclinical	RVU120 Sensitive: D – Preclinical